Immuno-oncology mainly focuses on the pathogenesis, prevention, diagnosis and treatment of tumors through the perspective of immunology, providing new ideas for cancer research.
CD Genomics offers you an efficient and cost-effective NGS-based immuno-oncology solution to assist you in better understanding tumor-immune interactions. Our immuno-oncology solution is a one-stop-shop from sample to report with clear and reliable advantages.
CD Genomics has been committed to providing NGS-based immuno-oncology solutions to global pharmaceutical and biotech companies to gain a deeper understanding of the molecular mechanisms underlying cancer development and the immune system's response to cancer. We hope our immuno-oncology services provide our clients with deeper knowledge and insights into cancer generation, metastasis, treatment and prognosis assessment. CD Genomics' immuno-oncology solutions mainly include sequencing services in the following aspects.
T cell receptors (TCR) and B cell receptors (BCR) are receptors that recognize antigens expressed on the surface of T cells and B cells, respectively. When activated, lymphocytes initiate immune responses that promote the specific binding of their receptors to antigens such as tumors. CD Genomics offers NGS-based high-quality TCR/BCR sequencing services to assist you in analyzing the immune status of tumors and thereby advancing the study of immuno-oncology mechanisms.
CD Genomics offers NGS-based high-resolution and high-accuracy human leukocyte antigen (HLA) typing sequencing analysis services that overcome high sequence homology and hyper-polymorphism to identify true HLA allelic diversity. Our systematic and standard bioinformatics analysis will ultimately provide you with a meticulous report of HLA typing results.
Based on high performance, high sensitivity and high throughput targeted NGS sequencing technology, CD Genomics can provide you with a variety of designed and customized cancer panel sequencing services to target specific genes or mutations more efficiently and accurately.
CD Genomics provides you with NGS-based tumor immune microenvironment analysis services that enable quantification of the relative infiltration of innate and adaptive immune cells (CD8+, CD4+, T cells, B cells, Treg cells, NK cells, macrophages, monocytes, neutrophils) by proprietary immune cell type-specific gene expression profiles.
We are convinced that CD Genomics is the partner you have been seeking for your immuno-oncology related research. Our automated sequencing platform and dedicated team of experts guarantee the accuracy of sequencing and analysis results. If you are interested in the immuno-oncology solutions offered by CD Genomics, please feel free to contact us.
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
